4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 91 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $367,883 | -22.6% | 21,401 | 0.0% | 0.00% | +50.0% |
| Q4 2022 | $475,316 | -75.9% | 21,401 | -91.3% | 0.00% | -83.3% |
| Q3 2022 | $1,971,000 | +15.2% | 245,123 | 0.0% | 0.01% | -53.8% |
| Q2 2022 | $1,711,000 | -53.8% | 245,123 | 0.0% | 0.03% | -42.2% |
| Q1 2022 | $3,706,000 | -31.1% | 245,123 | 0.0% | 0.04% | -16.7% |
| Q4 2021 | $5,378,000 | -27.5% | 245,123 | -10.9% | 0.05% | +74.2% |
| Q3 2021 | $7,421,000 | +12.0% | 275,123 | 0.0% | 0.03% | -16.2% |
| Q2 2021 | $6,625,000 | -44.7% | 275,123 | -0.4% | 0.04% | -43.1% |
| Q1 2021 | $11,986,000 | +398.6% | 276,294 | +376.4% | 0.06% | +242.1% |
| Q4 2020 | $2,404,000 | – | 58,000 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VR Adviser, LLC | 3,000,000 | $38,190,000 | 4.02% |
| Casdin Capital, LLC | 1,033,811 | $13,160,414 | 1.46% |
| BVF INC/IL | 4,007,413 | $51,014,367 | 1.38% |
| Deep Track Capital, LP | 2,778,107 | $35,365,302 | 1.36% |
| Opaleye Management Inc. | 308,500 | $3,927,205 | 1.28% |
| Eagle Health Investments LP | 437,911 | $5,574,607 | 1.23% |
| Novo Holdings A/S | 1,200,000 | $15,276,000 | 1.13% |
| RA Capital Management | 4,163,211 | $52,997,676 | 1.04% |
| VIKING GLOBAL INVESTORS LP | 4,787,914 | $60,950,145 | 0.25% |
| HighVista Strategies LLC | 33,419 | $425,424 | 0.20% |